(Q28342961)

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1303690

11 September 2022

K. S. Goh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1303690

11 September 2022

N. Guillou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1303690

11 September 2022

V. Labrousse

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1303690

Zentralblatt fur Bakteriologie : international journal of medical microbiology

11 September 2022

language of work or name

English

0 references

publication date

December 1992

0 references

published in

0 references

volume

277

0 references

issue

4

0 references

page(s)

474-84

0 references

cites work

Diagnosis and treatment of disease caused by nontuberculous mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Basis for Lack of Drug Susceptibility of Atypical Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

LM 427,a new spiropiperidylrifamycin: In vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

In vitro and in vivo activities of clarithromycin against Mycobacterium avium

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Permeability barrier to hydrophilic solutes in Mycobacterium chelonei

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Permeability of the mycobacterial cell wall

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Susceptibility of Mycobacterium avium complex to various two-drug combinations of antituberculosis agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Intracellular distribution and activity of antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980472-X

7 January 2021

10.1016/S0934-8840(11)80472-X

Identifiers

DOI

0 references

Fatcat ID

release_nmdd7d7vabh2bmemqkksvf5q2i

0 references